- Conditions
- Waldenström's Macroglobulinemia
- Interventions
- BGB-3111, Ibrutinib
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Duarte, California • Denver, Colorado + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2329–2352
of 7,463
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anhydramnios, Potter Syndrome, Lung Hypoplasia, Multicystic Dysplastic Kidney, Multicystic Renal Dysplasia, Bilateral, Lower Urinary Tract Obstructive Syndrome, Fetal Renal Anomaly
- Interventions
- Serial amnioinfusions with isotonic fluid, Spinal needle, Isotonic fluid
- Procedure · Device · Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 6 more
- Conditions
- Heart Failure, Acute Heart Failure
- Interventions
- Finerenone, Placebo
- Drug
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 72 more
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Granulocyte colony-stimulating factor plus plerixafor, Granulocyte colony-stimulating factor plus placebo
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 78 Years
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Duarte, California • Denver, Colorado + 23 more
- Conditions
- Chronic Pain
- Interventions
- Precision Spectra™ SCS system programming features
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Albany, New York
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Simtuzumab, Simtuzumab placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
- Conditions
- Breast Cancer
- Interventions
- docetaxel, paclitaxel
- Drug
- Lead sponsor
- Aventis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2004
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 28 more
- Conditions
- Cystic Fibrosis, Lung Infection, Cystic Fibrosis Pulmonary Exacerbation
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 7 more
- Conditions
- Head and Neck Cancer
- Interventions
- docetaxel, irinotecan hydrochloride
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Stanford, California • Aurora, Colorado + 33 more
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg, Efavirenz 600 mg, Rilpivirine 25 mg, Placebo, Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
- Conditions
- Sepsis
- Interventions
- Vitamin C, Thiamine, Hydrocortisone, Vitamin C Placebo, Thiamine Placebo, Hydrocortisone Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more
- Conditions
- Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Interventions
- BXCL501, Matching Placebo
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 24
- States / cities
- Bellflower, California • Cerritos, California • Culver City, California + 19 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 2.0 mg OPT-302, 0.5 mg ranibizumab, Sham
- Biological · Procedure
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 67 more
- Conditions
- Lung Cancer
- Interventions
- Biomarker (not used as an intervention)
- Device
- Lead sponsor
- Allegro Diagnostics, Corp.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 1,331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 17 more
- Conditions
- Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
- Interventions
- Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 5 Years to 60 Years
- Enrollment
- 1,875 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 404
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more
- Conditions
- Pregnancy, Child Development
- Interventions
- Choline, Placebo
- Drug · Dietary Supplement
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 351 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Temozolomide, Veliparib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 390
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 287 more
- Conditions
- Cervical Dystonia
- Interventions
- Botulinum toxin type A, Placebo
- Biological · Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 35 more
- Conditions
- Type1 Diabetes Mellitus
- Interventions
- Insulet automated glucose control system
- Device
- Lead sponsor
- Insulet Corporation
- Industry
- Eligibility
- 2 Years to 85 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Denver, Colorado • New Haven, Connecticut
- Conditions
- Lymphoma, T-Cell
- Interventions
- Genetic: MB-105
- Biological
- Lead sponsor
- March Biosciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- San Diego, California • Denver, Colorado • Tampa, Florida + 8 more
- Conditions
- OSA
- Interventions
- Aroxybutynin and Atomoxetine
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Chandler, Arizona + 80 more
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor, Breast Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Carcinosarcoma, Ovarian
- Interventions
- PHST001, Paclitaxel, Topotecan, Doxorubicin, FOLFIRI, FOLFOX, Gemcitabine, Mirvetuximab Soravtansine, Trastuzumab Deruxtecan
- Biological · Drug
- Lead sponsor
- Pheast Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pain questionnaires
- Behavioral
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 279
- States / cities
- Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 181 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Eluxadoline, Placebo
- Drug
- Lead sponsor
- Furiex Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 807 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 288
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 225 more